Review ArticlePain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis
Introduction
Of the 10 million patients diagnosed with cancer worldwide, pain is one of the most common, complex and persisting symptoms during and after cancer treatment.1 Pain during cancer treatment, equalized as acute pain in this systematic review, is defined as pain up to three months after treatment and chronic pain as the pain persistent for more than three months.2
Pain during cancer treatment can be caused by the cancer itself or by the different available treatment modalities.3 The most common treatment modalities are surgery, radiotherapy and chemotherapy.4 Acute postsurgical pain commonly exists after cancer surgery. This pain can either be neuropathic or nociceptive or a combination of both.5,6 The predictors of an increased severity of acute pain are, among other things, an increased duration of surgery and higher rates of pain catastrophizing before surgery.7 Furthermore, 90% of the oncological patients treated with neurotoxic chemotherapy develop chemotherapy-induced peripheral neuropathic pain and radiotherapy can also result in radiation-induced peripheral neuropathic pain and radiation-induced fibrosis.8, 9, 10
Despite the protective role of acute pain after these treatment modalities, acute pain can lead to a reduced general functioning in daily life.11 Furthermore, it also has an important impact on quality of life.12 The experience of pain may have an enormous impact on someone's mood, resulting in feelings of depression, an increase in anxiety and even cognitive dysfunctions.13 Moreover, acute cancer-related pain is also an important predictor for chronic pain after cancer treatment, which can lead to neuroplastic changes.7 Therefore, it is important to already be attentive of pain during cancer treatment, to improve daily functioning, quality of life and to prevent becoming chronic after treatment.
In 2016, a systematic review was published about the prevalence rates of pain during and after cancer treatment in all cancer stages.14 They included patients with head and neck, lung, breast, gastrointestinal, prostate, gynecological, and other cancer types and patients receiving anticancer treatment with curative or palliative intention.14 They concluded that pain is a prevalent and persistent symptom, with prevalence rates up to 55% during cancer treatment, even though the increased efforts to assess and manage pain related to cancer treatment.14
Several studies indicate that there are still some barriers for an effective pain management approach.15,16 Some important reasons for an undertreatment of pain are the fear of clinicians for addiction and side effects of the pain medication, limited knowledge of the use of pain education and even cultural beliefs of the clinician themselves.15 Furthermore, pain assessment is often not a priority for the health care professional and they often have limited knowledge of the several pain assessment methods.16
However, during the last five years, the awareness of acute pain during cancer treatment as a real health problem has increased through the availability of more officially endorsed guidelines on assessment and management of cancer-related pain.17, 18, 19 For example, the European Society for Medical Oncology clinical practice guidelines published in 2018 some important rules for an adequate pain assessment.17 In one way, increased attention and thus assessment of pain can result into an increase in pain prevalence rates. However, this can as well lead to an improvement in cancer-related pain management, which can in turn result in a decrease in pain prevalence rates. Therefore, the aim of this review was to provide a new overview of the pain prevalence rates during cancer treatment. Moreover, this overview will give more insight in the increasing need for an adequate pain assessment and pain management approach.
Section snippets
Methods
This systematic review was registered within the International Prospective Register of Systematic Reviews (PROSPERO reference CRD42016038870) on 11 November 2020 and adhered to the PRISMA statement recommendations.20
Study Search
The initial search resulted in 9052 studies (see Fig. 1). After removing duplicates, 7300 studies were screened on title/abstract. After title/abstract screening, 1740 studies were screened on full-text. Some of the authors (n = 93) were mailed to obtain essential information, whereof 81 studies were excluded because not receiving a response within a reasonable timeframe of two weeks or did not meet the predefined eligibility criteria. We contacted our third reviewer (A. D. G.) about 19 studies
Discussion
The aim of this systematic review was to give an overview of the pain prevalence rate during cancer treatment, five years after the last systematic review published on this topic.14 The overall pain prevalence rate was 40% (95%CI 0.29–0.51) during and up to three months after curative cancer treatment.
The previous systematic review of van den Beuken-van Everdingen et al. (2016) reported a higher pooled pain prevalence rate of 55% (95% CI 0.46–0.64) during cancer treatment, compared to our
Conclusion
This systematic review shows that, despite the development of new guidelines for pain assessment and pain management, there is still a high prevalence rate of pain during and up to three months after curative cancer treatment. Furthermore, there is a high heterogeneity in the reported pain prevalence rates between the different studies. These two findings emphasize the need for further investigations on adequate pain assessment and pain management approaches, during and within three months
Disclosures and Acknowledgments
This work was supported by the University of Antwerp [grant number 41776, 2020]. The authors declare no conflicts of interest.
References (70)
- et al.
Neuropathic pain in cancer
Br J Anaesth
(2013) - et al.
Late radiation injury to peripheral nerves
Handb Clin Neurol
(2013) - et al.
The ACTTION–APS–AAPM Pain Taxonomy (AAAPT) multidimensional approach to classifying acute pain conditions
J Pain
(2017) - et al.
Update on prevalence of pain in patients with cancer: systematic review and meta-analysis
J Pain Symptom Manage
(2016) - et al.
Cancer pain assessment and measurement
Semin Oncol Nurs
(2019) - et al.
Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement
J Clin Epidemiol
(2012) - et al.
Effects of pessimism, depression, fatigue, and pain on functional health-related quality of life in patients with resected non-advanced breast cancer
Breast
(2019) The psychometric properties of the hebrew version of the memorial symptom assessment scale (MSAS-Heb) in patients with breast cancer
J Pain Symptom Manage
(2015)- et al.
A prospective trial comparing pain and quality of life measures after anatomic lung resection using thoracoscopy or thoracotomy
Ann Thorac Surg
(2014) - et al.
The measurement of clinical pain intensity: a comparison of six methods
Pain
(1986)
The validity and reliability of pain measures in adults with cancer
J Pain
Chronic pain and medullary descending facilitation
Trends Neurosci
Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit
J Pain Symptom Manage
How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis
Pain
Aromatase inhibitor-associated arthralgia syndrome
Breast
Multiple session experimental pain measurement
Pain
Management of postoperative pain: a clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists’ committee on regional anesthesia, executive commi
J Pain
Skin: histology and physiology of wound healing
Facial Plast Surg Clin North Am
Occurrence of cancer pain
J Natl Cancer Inst Monogr
Assessment of the evolution of cancer treatment therapies
Cancers (Basel)
Re-visiting post-breast surgery pain syndrome: risk factors, peripheral nerve associations and clinical implications
Gland Surg
Persistent pain after breast cancer treatment: A questionnaire-based study on the prevalence, associated treatment variables, and pain type
J Breast Cancer
Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study
Reg Anesth Pain Med
Radiation-induced fibrosis: mechanisms and implications for therapy
J Cancer Res Clin Oncol
Quality of life among cancer patients
Indian J Palliat Care
Cancer pain–a provoker of emotional, social and existential distress
Acta Oncol
Exploring factors among healthcare professionals that inhibit effective pain management in cancer patients
Cent Eur J Nurs Midwifery
Management of cancer pain in adult patients: ESMO clinical practice guidelines
Ann Oncol
Adult cancer pain, Version 3.2019, NCCN clinical practice guidelines in oncology
J Natl Compr Canc Netw
Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors
JAMA Oncol
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
BMJ
Chronic wounds: factors influencing healing within 3 months and nonhealing after 5â "6 months of care
Wounds
Exploring the transition from curative care to palliative care: a systematic review of the literature
BMJ Support Palliat Care
Cited by (26)
The effectiveness of online pain management education on the patient related barriers to cancer pain management: A randomized controlled trial
2023, European Journal of Oncology NursingPerceived discrimination and physical activity mediate the associations between receiving a survivorship care plan and cancer pain
2022, Cancer EpidemiologyCitation Excerpt :Cancer survivors’ pain can result from cancer, including tumor cells pressing on nerves or internal organs, or from cancer treatment(s). Furthermore, 40% of cancer survivors experience pain [4] and 66% of survivors with advanced conditions report some degree of pain [5], which negatively affects cancer survivors’ social and physical functioning and psychological well-being [6]. Minimizing pain, which is vital for improving survivors’ quality of life [7], can be achieved through education, lifestyle modification, medication therapies, and integrative methods [8,9].
Metabolic underpinnings of cancer-related fatigue
2024, American Journal of Physiology - Endocrinology and MetabolismThe role of spirituality in pain experiences among adults with cancer: an explanatory sequential mixed methods study
2024, Supportive Care in Cancer